Effectiveness of a brief psychoeducational group intervention for relatives on the course of disease in patients after inpatient depression treatment compared with treatment as usual – study protocol of a multisite randomised controlled trial

Fabian Frank¹², Juliette Wilk¹, Levente Kriston³, Ramona Meister³, Shinji Shimodera⁴, Klaus Hesse⁵, Eva-Maria Bitzer², Mathias Berger¹ and Lars P. Hölzel"*

Abstract

**Background:** Relapses and rehospitalisations are common after acute inpatient treatment in depressive disorders. Interventions for stabilising treatment outcomes are urgently needed. Psychoeducational group interventions for relatives were shown to be suitable for improving the course of disease in schizophrenia and bipolar disorders. A small Japanese monocentre randomised controlled trial also showed promising results for depressive disorders. However, the evidence regarding psychoeducation for relatives of patients with depressive disorders is unclear.

**Methods/Design:** The study is conducted as a two-arm multisite randomised controlled trial to evaluate the incremental effect of a brief psychoeducational group intervention for relatives as a maintenance treatment on the course of disease compared to treatment as usual. Primary outcome is the estimated number of depression-free-days in patients within one year after discharge from inpatient treatment. 180 patients diagnosed with unipolar depressive disorders as well as one key relative per patient will be included during inpatient treatment and randomly allocated to the conditions at discharge. In the intervention group, relatives will participate in a brief psychoeducational group intervention following the patient’s discharge. The intervention consists of four group sessions lasting 90 to 120 min each. Every group session contains informational parts as well as structured training in problem-solving. In both study conditions, patients will receive treatment as usual. Patients as well as relatives will be surveyed by means of questionnaires at discharge and three, six, nine and twelve months after discharge. In addition to the primary outcome, several patient-related and relative-related secondary outcomes will be considered and health economics will be investigated.

**Discussion:** Our study will provide evidence on the incremental effect of a brief psychoeducational intervention for relatives as a maintenance treatment after inpatient depression treatment. Positive results may have a major impact on health care for depression.

(Continued on next page)
Background

Relapses and rehospitalisations are common in depressive disorders [1–3], although high pre-post effects have been shown for inpatient depression treatment in routine care [4], and a pharmacotherapeutic and/or psychotherapeutic maintenance therapy can reduce the probability of relapses [5]. Interventions for stabilising positive outcomes of depression treatment are therefore urgently needed. For other mental disorders, psychoeducation for relatives has been shown to be suitable for improving patient-relevant outcomes, e.g., relapse, rehospitalisation or employment rate [6–10]. These interventions focus on the information needs of relatives (e.g., [11–13]) as well as on reciprocal interactions between illness-related burden and high expressed emotion in relatives regarding relapses in patients (e.g., [14–16]). For depressive disorders too, the efficacy of a brief psychoeducational group intervention for relatives (PGIR) was initially investigated regarding the relapse rate of patients after discharge from inpatient treatment in a first Japanese randomised controlled trial conducted by Shimazu et al. [17]. Patients of both study conditions were treated fortnightly, with the consultation including an evaluation of depressive symptoms and psychopharmacological and psychotherapeutic treatment. In the intervention group, the relatives took part in a PGIR, which consisted of four group sessions of about 90 to 120 minutes on a fortnightly basis, addressing “epidemiology and causes”, “symptoms”, “treatment and course” and “coping with the patient” as well as group discussions for problem-solving. Relatives participating in the control group did not receive any intervention. The relapse rate in the intervention group was about 8 % within nine months after discharge, in contrast to 50 % in the control group. The study revealed a statistically and clinically significant incremental effect to the psychiatric maintenance treatment. However, in view of differences in health care systems [18] as well as cultural differences, e.g., regarding beliefs about mental illnesses or denotation of symptoms [19, 20], the intervention and the results of the study cannot be directly transferred to Western countries. Moreover, the study was monocentric, with only a small sample size (N = 57). As small monocentre trials tend to show higher effect sizes, and results are statistically more uncertain than in multicentre trials with a larger sample size [21, 22], the results are further restricted. The primary endpoint of the study was the time until relapse occurred, which is a clinically relevant criterion. However, the phasic course of depressive disorders is insufficiently reflected by this criterion. Despite these limitations, the results of Shimazu et al. [17] are encouraging, and are in line with results for psychoeducation for relatives in other mental disorders [7–10]. Therefore, the intervention of Shimazu et al. [17] was culturally adapted [23]. As randomised controlled multicentre trials are lacking, and the evidence on the effects of PGIR as a maintenance treatment after inpatient depression treatment is unclear, further research is required to close this evidence gap.

Objectives

The aim of our study is to evaluate the incremental effect of a short PGIR as a maintenance treatment after inpatient depression treatment in improving the course of illness in patients compared to treatment as usual (TAU). We hypothesise that PGIR is more effective in improving the course of illness than TAU alone. Additionally, we aim to assess secondary outcomes on the patient and relative level as well as health economics on a societal level.

Methods/Design

Study design

The effects of a brief PGIR as a maintenance treatment after inpatient depression treatment will be investigated by means of a two-arm parallel-group randomised controlled multicentre trial using five measurements on the patient and on the relative level within one year after discharge of the patient (T0 = at discharge; T1 = 3; T2 = 6; T3 = 9; T4 = 12 months after discharge). The following eight study centres will be involved in the trial:

1. Department of Psychiatry and Psychotherapy, Medical Centre – University of Freiburg (primary study centre) combined with the Department of Psychosomatic Medicine and Psychotherapy, Medical Centre for Psychiatry Emmendingen;
2. Department of Psychiatry and Psychotherapy, University Medical Centre Tübingen;
3. Department of Psychiatry and Psychotherapy, University Medical Centre Leipzig;
4. Department of General Psychiatry, University Medical Centre Heidelberg;
5. Department of Psychiatry and Psychotherapeutic Medicine, Municipal Hospital Karlsruhe;
6. Department of Psychiatry and Psychotherapy, Vitos Medical Centre Hadamar;

Keywords: Depression, Psychoeducation, Family intervention, Relatives, Randomised controlled trial
7. Department of Psychiatry, Psychotherapy and
Psychosomatics, Vivantes Hospital am Urban Berlin;
8. Department of General Psychiatry and
Psychotherapy West, Medical Centre for Psychiatry
Weinsberg.

In order to enhance generalisability, we chose different
types of hospitals as study centres, including university
medical centres, psychiatric wards of general hospitals as
well as large psychiatric centres.

Oversight of research with human participants
The study has been approved by the Ethics Review
Committee of the University Medical Centre Freiburg
(number: 381/13) and the local Ethics Review Com-
mittees responsible for the participating sites (Ethik-
Kommission an der Medizinischen Universität Leipzig,
number: 346-14-17112014; Ethik-Kommission an der
Medizinischen Fakultät der Eberhard-Karls-Universität
und am Universitätsklinikum Tübingen, number 544/
2014BO2; Ethik-Kommission der Medizinischen Fakultät
Heidelberg, number: S-061/2015; Landesärztekammer
Baden-Württemberg, number: B-F-2014-093; Ethik-
Kommission bei der Landesärztekammer Hessen, num-
ber: MC 291/2014). Written informed consent is provided
by all study participants prior to data collection, random-
isation and intervention. To foster quality assurance and
patients’ safety, an advisory board has been implemented,
which advises the study protocol, study procedures and
realisation of the study. Additionally, trial sites will be
visited by a study monitor twice during the recruitment
period to ensure compliance with ethical principles
and the study protocol, as well as to check data quality
and accuracy.

Inclusion and exclusion criteria
The study population consists of patient-relative tan-
dems. Patients aged 18 years or older treated primarily
for a unipolar depressive disorder according to the Inter-
national Classification of Disease, 10th revision (ICD-10:
F32.xx, F33.xx) will be included. Additionally, a key rela-
tive (at least 18 years of age), who is named by the pa-
tient, has to be willing to participate in the PGIR.
Following current recommendations for psychoeduca-
tion in relatives, the relative does not have to be a family
member, but the patient does have to feel attached to
this person [24]. The participating relatives have to live
in close proximity to the respective study centre, as par-
ticipation in the PGIR has to be feasible. To ensure that
data can be gathered by questionnaires and that relatives
are able to participate in the PGIR, patients and relatives
need to be able to read and write in German. Moreover,
patients and relatives have to be able to give informed
consent. Patients will be excluded if they are diagnosed
with comorbid dementia (ICD-10: F00.x), substance de-
pendence (ICD-10: F1x.2), schizophrenia (ICD-10: F20.x),
schizoaffective disorder (ICD-10: F25.x), bipolar disorder
(ICD-10: F31.x) or borderline personality disorder
(ICD-10: F60.31). To ensure a high external validity of our
results, no additional exclusion criteria are formulated.

Recruitment and eligibility screening
Patient-relative tandems will be recruited at the above-
mentioned sites while patients are being treated in in-
patient depression treatment. At each study centre, one
therapist, who serves as a contact person for the leading
study centre, will be responsible for the recruitment.
The recruitment procedure is identical at each site
according to the following step-by-step routine:

1. By periodically screening new admissions in routine
health records of the respective study centre,
potentially eligible patients will be identified;
2. Patients identified as potentially eligible in step one
will be informed about the study verbally as well as
through written study information;
3. If the patient is willing to participate in the trial, the
diagnosis will be confirmed using the International
Diagnostic Checklist for ICD-10 [25, 26];
4. If the patient is eligible and informed consent has
been obtained, eligibility will be screened in the
relative named by the patient and informed consent
will be obtained from the relative.

To facilitate a consistent implementation across all
sites, each procedure is described in detail in a recruit-
ment guideline. For each recruited and randomised
patient-relative tandem, an allowance of € 50 will be
paid to the recruiting staff. Recruitment will continue
until the target population has been achieved. The enrol-
ment period will extend over 12 months.

Intervention and control group
The intervention follows that of Shimazu et al. [17], but
had to be modified in some aspects in order to fit with
German conditions. The process of adaptation was based
on the results of our own studies [13, 23, 27]. The PGIR
will be conducted in a multifamily setting with one key
relative per patient and the patient being absent. Groups
will consist of three to five relatives. The PGIR consists
of four group sessions, which will be conducted on a
fortnightly basis. It will begin after discharge of the pa-
tient from inpatient depression treatment. Group ses-
sions will be held by one therapist who possesses at least
a Master’s degree or equivalent, and will last 90 to
120 min each. The intervention has two main compo-
nents: Each group session consists of about 45 min of
provision of information, while the remaining time is used for training problem-solving skills following the approach of Nezu et al. [28] as well as Hegel et al. [29]. The informational parts cover (1.) symptoms, epidemiology, course and prognosis of depressive disorders; (2.) support services for relatives as well as sources of personal strength and problem areas; (3.) cause of illness and (4.) treatment of depressive disorders. Problem-solving skill training is a brief intervention which has shown high efficacy in several diseases both in patients [30] and in relatives [31]. The PGIR aims to reduce caregiver burden and expressed emotion by teaching relatives how to systematically solve psychosocial problems. To evaluate the incremental effect of the intervention, the PGIR will be compared to treatment as usual (TAU), which in Germany mostly consists of psychotherapeutic and/or pharmacotherapeutic outpatient maintenance treatment provided by psychotherapists, psychiatrists or general practitioners [5]. In the intervention group, the only additional intervention to TAU will be the PGIR. In the control group, there will be no systematic information or psychoeducational intervention offered to relatives. To fit with routine care conditions, neither the inpatient treatment before discharge nor the patient treatment after discharge will be restricted in any way in the intervention group or the control group.

Postulated mechanism of action

By introducing information provision and problem-solving skills training as central components of the intervention, the model of change induced by the PGIR is expected to lead to proximal effects on relatives. These effects are thought to influence the patient-relative dyad and might ultimately exert a distal effect by improving the course of illness in patients (c.f. Fig. 1).

First, it is supposed that information provision improves depression literacy in relatives. In this respect, the disease-related burden will be reduced by fostering the understanding and handling of illness-related phenomena [32]. Second, it is assumed that the problem-solving skill training increases the problem-solving competence in relatives. Accordingly, the psychosocial and the disease-related burden will be reduced, as burdensome day-to-day and disease-related problems – e.g., regarding self-care and dealing with the patient – can be more frequently solved. As there are reciprocal interactions between burden on relatives and expressed emotion in relatives [14, 15], these paths are likely to reduce expressed emotion in the patient-relative dyad. Expressed emotion constitutes an indicator of distress in families, taking into account criticism and emotional overinvolvement [16, 33]. It can be distinguished into high expressed emotion and low expressed emotion, with the former having been shown to be a powerful predictor of relapses in patients with depressive disorders after inpatient treatment [16, 34]. Therefore, it is supposed that positive changes on the expressed emotion level might lead to reduced depressive symptoms on the patient level.

Administration

Patient-relative tandems will be screened for eligibility and recruited by the responsible therapists at the respective study centres during inpatient treatment. Informed consent will be sought from all participating patients and relatives (−T₁, enrolment, c.f. Table 1). At
| Time point | Study period | Enrolment | Baseline | Allocation | Intervention | Follow-up |
|------------|--------------|-----------|----------|------------|--------------|-----------|
| -T1        | -T0          | T0        | T1       | T2         | T3           | T4        |

**Enrolment**

- Patients and relatives
  - Eligibility screening: x
  - Informed consent: x

**Allocation**

- Psychoeducational group intervention: x

**Intervention**

- Adherence and competence of therapists\(^a/IG\): x

**Self-rating**

- Patient-related
  - Symptom self-rating (PHQ-9, Core set): x
  - Rehospitalisations (FIMA, CSSRI-D): x
  - Health care and medication consumption (FIMA, CSSRI-D): x
  - Employment status\(^a\): x
  - Days of incapacity to work (DEGS): x
  - Functional capability, activity and participation (WHODAS 2.0): x
  - General state of health (DEGS): x
  - Perceived expressed emotion (FEF): x
  - Perceived criticism (PCS): x
  - Adverse events\(^a/IG\): x
  - Clinical characteristics\(^a\): x
  - Demographic information\(^a\): x

- Relative-related
  - Psychosocial burden (SCL-K-9): x
  - Disease-related burden (IEQ-EU): x
  - General state of health (DEGS): x
  - Problem-solving competency (SPSI-R-S): x
  - Implementation of problem-solving\(^a\): x
  - Depression literacy (D-Lit)\(^a\): x
  - Control attributions (IPQS-R): x
  - Expressed emotion (FQ): x
  - Health care utilisation (FIMA): x
  - Employment status\(^a\): x
  - Acceptance and subjective benefit of the intervention\(^a/IG\): x
  - Adverse Events\(^a/IG\): x
  - Demographic information\(^a\): x

\(^{-}T_0\) during inpatient treatment; \(T_0\) at discharge from inpatient treatment; \(T_A\) allocation to intervention or control group; \(T_{Int}\) intervention; Follow-up: \(T_1 = 3\) months; \(T_2 = 6\) months; \(T_3 = 9\) months; \(T_4 = 12\) months after discharge from inpatient treatment; CSSRI-D, German version of the Client Sociodemographic and Service Receipt Inventory; DEGS, German Health Interview and Examination Survey for Adults; D-Lit, Depression Literacy Test; FEF, Questionnaire on Family Atmosphere; FIMA, Questionnaire for Health-Related Resource Use; FQ, German version of the Family Questionnaire; IEQ-EU, German Version of the Involvement Evaluation Questionnaire; IPQS-R, scales for control attributions of the Illness Perception Questionnaire for Schizophrenia: Relatives’ version; PCS, Perceived Criticism Scale; PHQ-9, 9-item version of the Patient Health Questionnaire; SCL-K-9, 9-item version of the Symptom-Checklist-90-R; SPSI-R-S, 25-item version of the Social Problem-Solving Inventory-Revised; WHODAS 2.0, 36-item version of the WHO Disability Assessment Schedule; *self-constructed items; \(^a\)only administered in the intervention group.
discharge from inpatient depression treatment, a baseline investigation in patients will be conducted in the respective study centres using questionnaires \( (T_0, \text{baseline}) \). At the same time, a baseline investigation in relatives will be centrally provided by the leading study centre using questionnaires sent by post \( (T_0, \text{baseline}) \). Subsequent to the baseline investigation, patient-relative tandems will be randomly allocated to the intervention or the control group by the leading study centre \( (T_A, \text{allocation}) \). As blinding of patient-relative tandems and therapists is not feasible due to the nature of the intervention, patient-relative tandems as well as therapists will be informed about the allocation by the leading study centre \( (T_A, \text{allocation}) \). In the intervention group, the intervention should begin as soon as possible after discharge from inpatient depression treatment \( (T_{\text{Int}}, \text{intervention}) \). For each relative participating in the PGIR, the therapist in charge receives an allowance of € 50 per group session. For the follow-up examinations in patients and relatives \( (T_1 = 3 \text{ months}; T_2 = 6 \text{ months}; T_3 = 9 \text{ months}; T_4 = 12 \text{ months after discharge}) \), postal questionnaires provided by the leading study centre will be used. To ensure a sufficient response rate at each time point, patients as well as relatives will receive an unconditional reimbursement of € 5 sent by post together with each questionnaire. In addition, pre-stamped envelopes will be added for returning the questionnaires, as these measures are associated with a better response rate \[35\]. If patients and/or relatives do not respond, they will be reminded by post after two weeks and by telephone after four weeks.

**Primary outcome**

The primary outcome is the estimated number of depression-free-days (DFDs) on the patient level. This is a valid and well-established measure which takes into account the course of disease and the change in symptoms over time. Moreover, it is clinically well comprehensible \[36, 37\]. In a study on the relationship between patient-relative conflicts and long-term depression outcomes, DFDs were proven to be change-sensitive \[38\]. DFDs will be based on the Patient Health Questionnaire (PHQ-9) \[39\] measured at five time points \( (T_0 - T_4) \) and calculated according to Lave et al. \[40\] and Vannoy et al. \[41\]. The PHQ-9 shows good psychometric properties \[42\] and is recommended by the DSM-5 and current guidelines for unipolar depression for measuring symptom severity in depressive disorders \[5, 43\].

**Secondary outcomes**

Secondary outcomes are addressed on the patient and relative level. On a societal level, health economics are considered as a secondary outcome. All measurement instruments employed to measure primary and secondary outcomes as well as all of the measurement time points at which they are applied are shown in Table 1.

**Patient level**

Rehospitalisations within the first year after discharge from inpatient treatment, including time until rehospitalisation, will be considered as a secondary outcome (measurement based on the FIMA \[44\] and the CSSRI-D \[45\]; time points \( T_1 - T_4 \)). Furthermore, health care utilisation and medication consumption will be assessed (measurement based on the FIMA \[44\] and the CSSRI-D \[45\]; time points \( T_1 - T_4 \)). Additionally, employment status (self-constructed items; time points \( T_0 - T_4 \)) and days of incapacity to work (measurement based on the DEGS \[46\]; time points \( T_1 - T_4 \)) will be measured as secondary outcomes. Rehospitalisation and incapacity to work are relevant outcomes as they are objective indicators of the course of disease. As these outcomes – as well as health care utilisation and medication consumption – are also associated with costs, they are also important from a health economic point of view. As psychoeducation for relatives was shown to be effective for patients’ employment rate for other severe mental disorders \[6\], and evidence in depression is so far lacking, this was chosen as a secondary outcome. Depressive disorders can lead to impairment of functional capability, activity and participation \[47\] and affects the general state of health \[48\]. Therefore, these are relevant outcomes to judge the effect of the intervention beyond the course of disease (measured by the WHODAS 2.0 \[49\] and a global item regarding the general state of health according to the DEGS \[46\]; time points \( T_0 - T_4 \)). As expressed emotion is a powerful predictor of relapses in depressive disorders \[16\], and the intervention is likely to modify the level of expressed emotion, perceived expressed emotion (measured by the FEF \[50, 51\]; time points \( T_0, T_2, T_4 \)) as well as perceived criticism (measured by the PCS \[51, 52\]; time points \( T_0, T_2, T_4 \)) are interesting intermediate outcomes to understand how the intervention works. In line with the requirement to report potential harm in patients \[53\], adverse events following the intervention will be assessed in the intervention group (self-constructed items; time points: \( T_2, T_4 \)).

**Relative level**

Relatives of patients with depressive disorders experience psychosocial burden \[54–56\]. Therefore, psychological distress (measured by the SCL-K-9 \[57\]; time points \( T_0 - T_4 \)) and disease-related burden (measured by the IEQ-EU \[58, 59\]; time points \( T_0 - T_4 \)) were chosen as outcomes to evaluate the effect of the intervention on the relative level. As caregiver burden can affect the health status of relatives \[60\], the general health status was chosen as an additional outcome to judge the effect of the intervention (measured by a
global item regarding the general state of health according to the DEGS [46]; time points: T₀ – T₄). As problem-solving competency is considered as a key competency for a healthy family atmosphere [61], this is considered as a secondary outcome (measured by the SPSI-R S [62, 63]; time points: T₀, T₂, T₄). In this regard, the relatives’ implementation of the problem-solving technique conveyed during the intervention is seen as a mediator of the effects (self-constructed items; time points: T₂, T₃, T₄). To capture further proximal effects of the intervention, depression literacy will be assessed (measured by the D-Lit [64] and self-constructed items; time points: T₀, T₂). In addition, control attributions will be examined (measured by scales on control attributions from the IPQS-R [65, 66]; time points: T₀, T₂, T₄), as these can be important factors for the development of expressed emotion [65]. Furthermore, expressed emotion will be assessed as an intermediate outcome (measured by the FQ [67]; time points: T₀, T₂, T₄). As burden on relatives can also be changed by using various health care services, health care utilisation will be assessed (measurement based on the FIMA [44]; time points: T₀ – T₄). As caring for a mentally ill person might have an impact on employment activity, employment status will be assessed (self-constructed items; time points: T₀ – T₄).

To judge the intervention from the relatives’ point of view, acceptance and the subjective benefit of the PGIR will be secondary outcomes (self-constructed items; time points: T₂). Following current recommendations [53] and research suggesting potential negative experiences of participants in group settings [68], adverse events will be assessed in the intervention group (self-constructed items; time points: T₂, T₄).

Additional parameters
Data on the following demographic parameters will be collected via self-report questionnaire in patients and relatives: age, sex, mother tongue, education, relationship and shared household with the relative, household size, health insurance status (self-constructed items; time point: T₀). On the patient level, data on clinical characteristics will be gathered regarding: medication, previous depressive episodes and previous inpatient treatment, duration of the current depressive episode, first onset of the depressive disorder and self-rated quality of the current inpatient treatment (self-constructed items; time point: T₀).

Health economics
A cost-effectiveness analysis (CEA) will be undertaken from the perspective of the statutory health insurance and the society as a whole. A CEA expresses costs in monetary units and outcomes in non-monetary units. Units used for outcomes will be: (1) DFDs, (2) prevented sick leave days, and (3) prevented rehospitalisations. Costs of TAU and of the intervention will be considered according to German guidelines on health economic evaluation [69]. We will consider both direct medical costs and indirect costs due to loss of productivity. Standardised and validated questionnaires (c.f. Table 1) will be used to obtain data about consumption of health resources [44], which will be monetised following current recommendations [70] to illustrate direct medical costs. The incremental cost-effectiveness ratio of the intervention for DFDs, prevented sick leave days and prevented rehospitalisations will be calculated. A budget impact analysis will be conducted along with the economic evaluation to best inform the needs of decision makers regarding affordability and cost-effectiveness of the intervention.

Measures taken to minimise/avoid bias

**Randomisation and concealment of allocation**
To control for known and unknown confounders and thus preclude selection bias, randomisation of patient-relative tandems will be conducted by means of a computer-based algorithm. Randomisation lists will adhere to a one-to-one study-group allocation ratio and will be stratified by centres with dynamically adaptable block sizes to prevent predictability and to ensure a balanced proportion of participants in both study conditions. To meet the challenges of a group intervention, randomisation blocks will include blocks with two, four, six, eight and ten patient-relative tandems. In each block size, the proportion of patient-relative tandems which will be allocated to the intervention or the control group is balanced. Once a study centre has recruited at least six patient-relative tandems, randomisation will be conducted with the appropriate block size. If a study centre has recruited two or four more patient-relative tandems before the first group session in the intervention group has taken place, they can be re-randomised and added to the PGIR and the control group. Randomisation lists will be centrally generated by the study statistician, who has no direct contact with clinicians or patient-relative tandems. To ensure allocation concealment, randomisation lists will be inaccessible to staff involved in the recruitment at the respective study centres. After recruitment of at least six patient-relative tandems (conducting the PGIR has to be feasible), study sites will report included patient-relative tandems to the leading study centre, which will report the allocation to the study sites as well as the patient-relative tandems. As the effect of the intervention was not moderated by any investigated variable in the study by Shimazu et al. [17], stratification for clinical characteristics will not be considered. However, central clinical variables (e.g., number of
depressive episodes, duration of the current episode) will be gathered and their effects will be investigated in additional sensitivity analyses.

**Documentation of recruitment**

The recruitment of the study sample will be documented in detail in order to judge the representativeness of included patients compared to the basic population of inpatients in depression treatment in the included study sites. Basic socio-demographic data and specific reasons for refusal of study participation of all screened patients and relatives, as well as exclusions of screened patients due to the above-mentioned exclusion criteria, will be closely documented. Therefore, a standardised operating protocol regarding the process of recruitment and informing patients as well as relatives has been developed.

**Blinding**

Due to the nature of the intervention, blinding of therapists and patient-relative tandems is not feasible. The primary outcome will be analysed by the study statistician, who will be blinded to the allocation of patients.

**Control of intervention adherence**

The intervention will be manualised and all related materials (e.g., slides, handouts) are standardised and will be provided by the leading study centre. Additionally, therapists will be trained in conducting the intervention within an intensive workshop to ensure process quality and standardisation of the intervention. Training success will be verified by using simulated therapy situations in the style of the Objective Structured Clinical Examination (OSCE). Only staff reaching a previously defined standard will be authorised to conduct the intervention within this trial. To further ensure the integrity of the intervention, the leading study centre will provide supervision as well as peer consultation via telephone or video conference. Finally, group sessions will be audiotaped and rated using self-developed scales [71] to judge the adherence and competence of therapists (T\text{int}, intervention, c.f. Table 1).

**Control of treatment-related confounders**

As the intervention is compared to TAU, and the treatment of the patient is not restricted in any way in either condition, different types of treatment received by the patients might influence the effects. Therefore, data on treatment received after discharge will be gathered on both the patient and the relative level (c.f. Table 1) and their effects will be investigated using sensitivity analyses.

**Statistical methods**

**Analyses**

The primary outcome, i.e., estimated DFDs one year after discharge from inpatient depression treatment, will be analysed by means of an analysis of covariance (ANCOVA) (independent variables: intervention, study centre; dependent variable: DFDs; covariate: severity of depressive symptoms at baseline) comparing the number of DFDs one year after discharge from inpatient depression treatment between the intervention and the control group. The primary analysis will be performed according to the intention-to-treat principle including all randomised patients. Multiple imputations will be used to account for missing data. Analyses with an alternative method of dealing with missing data and using available data will only be performed as sensitivity analyses in order to test the robustness of the findings. Secondary interval-scaled outcomes will be tested using t-tests and analyses of covariance (ANCOVA, if baseline measurement of the outcome is available). Dichotomous outcomes will be analysed using Fisher’s exact test, chi-square test (depending on expected cell frequencies), or logistic regression (if covariates are present). To ensure the interpretability of the results, each inferential statistical analysis will be accompanied by descriptive analysis. Differences in time until rehospitalisation will be analysed using Cox regression. For parameters in which the variance cannot be calculated analytically (e.g., cost-effectiveness), bootstrap methods will be used. Longitudinal analyses will be performed using general (interval-scaled outcome) or generalised (binary or ordered categorical outcome) linear mixed models. For the primary confirmatory analysis, a result with a type-I error under 5 % (\( p < 0.05 \)) will be considered as statistically significant. Every additional analysis is seen as exploratory. Accordingly, a correction of the type-I error inflation will not be applied.

**Sample size calculation**

The effect of the intervention in the study by Shimazu et al. [17] corresponds to an odds ratio of 0.09 (IG: 8 vs. CG: 50 % relapses), equivalent to a Cohen’s d of 1.33, which can be considered as a very large effect. However, the sample size was comparatively small, consisting of only 57 patient-relative tandems. Furthermore, there are some major differences to our study. First, the intervention in our study will be conducted by different therapists at several study sites. Second, our study is closer to routine conditions. Therefore, our study population will be more heterogeneous than in the study by Shimazu et al. [17]. A sample size of 128 patient-relative tandems one year after discharge (\( T_0 \)) is sufficient to detect a moderate effect of Cohen’s d = 0.50 (Cohen’s f = 0.25) with a power of 80 % by analysing the primary outcome via ANCOVA. In the study by Shimazu et al. [17], the
dropout rate was about 5%. As our study will be conducted under routine conditions, we estimate a conservative dropout rate of 10% (N = 18) for the time of the intervention and a further 20% lost to follow-up (N = 32). To reach a sample size of 128 patients under consideration of a total dropout rate of 30%, a total of 180 patient-relative tandems shall be randomised.

Discussion

Our study will provide information on the effects of PGIR as a maintenance treatment after inpatient depression treatment on central patient-related as well as relative-related outcomes, such as course of disease and therapists functioning in patients, as well as caregiver burden and expressed emotion in relatives. The PGIR approach evaluated within this trial fair very well in one small monocentre trial with a small sample size [17] but has never been evaluated within a multicentre trial. This is important, as small studies tend to overestimate effect sizes [21, 22]. The confirmation in a multisite study is therefore required. The brief intervention of our study is highly suitable for routine conditions regarding psychoducation for relatives of patients in inpatient depression treatment [27]. The results of our study will be important, as they will close an evidence gap and can therefore clarify recommendations in current guidelines [5] and eventually foster the provision of PGIR as a sensible addition to depression treatment.

Potential limitations of our study include the fact that blindness of patients and relatives as well as therapists is not feasible. Furthermore, patients will differ widely regarding their clinical characteristics due to the broad inclusion criteria. Additionally, the group of relatives will be heterogeneous, as we are not focusing on a specific group of relatives, such as partners. Moreover, treatment and health care utilisation of patients and relatives will not be restricted. These aspects might dilute the effects of the intervention. However, this can also be seen as strength of our study, as the study population is likely to come close to routine conditions and hereby can ensure a high external validity of the results. A further limitation is that study participants have to self-administer a high number of measurement instruments. This might hinder the feasibility of the trial and reduce the response rate.

Relapse and rehospitalisations are major topics after inpatient depression treatment. PGIR is a highly promising approach to improve the course of disease in this burdensome disorder. However, high-quality studies dealing with PGIR as an additional intervention to stabilise outcomes after inpatient depression treatment are largely lacking.

Trial status

Enrolment for the trial began in March 2015. At the time of manuscript submission, participants were still being recruited. Recruitment is expected to continue until March 2016. Data collection is expected to continue until March 2017.

Abbreviations

ANCOVA: Analysis of covariance; CEA: Cost-effectiveness analysis; CSSR-D: German version of the client sociodemographic and service receipt inventory; DFGS: German health interview and examination survey for adults; DFDs: Estimated number of depression-free-days; D-Lit: Depression literacy test; DRKS: German clinical trials register; FEF: Questionnaire on family atmosphere; FINA: Questionnaire for health-related resource use; FQ: German version of the family questionnaire; ICD-10: International classification of disease, 10th revision; IQEQ-EU: German version of the involvement evaluation questionnaire; IPQ-R: Scales for control attributions of the illness perception questionnaire for schizophrenia: relatives’ version; OSCE: Objective structured clinical examination; PCS: Perceived criticism scale; PHQ-9: 9-item version of the patient health questionnaire; PGIR: Psychoeducational group intervention for relatives; SCL-K-9: 9-item version of the symptom-checklist-90-R; SPSI-R-S: 25-item version of the social problem-solving inventory-revised; TAU: Treatment as usual; UTN: Universal trial number; WHODAS 2.0: WHO disability assessment schedule.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

FF participated in formulating the research question, was centrally involved in conceptualising and designing the study as well as developing the intervention, coordinates the study and drafted the first version of the manuscript. JW participated in developing the intervention as well as the coordination of the study and helped to draft the manuscript. LK and RM contributed substantially to the study design and the planning of the statistical analyses. SS gave support in developing the intervention and facilitated in conceptualising the study. EMB made contributions to the study design and the development of the intervention. MB provided administrative support and contributed to designing the study. KH made contributions to the concept and design of the study. LPH is the primary investigator, formulated the research question, conceptualised and designed the study and edited various drafts of the paper. All authors revised the manuscript critically for important intellectual content and read and approved the final manuscript.

Acknowledgements

This study is funded by the Else Kröner-Fresenius-Stiftung (2013_A290). The sponsor has reviewed and approved a previous version of this protocol in the context of the grant application process. The article processing charge was funded by the German Research Foundation (DFG) and the Albert-Ludwigs-University Freiburg in the funding programme Open Access Publishing. We thank Prof. Dr. Martin Härter, Prof. Dr. Martin Hautzinger, Prof. Dr. Elisabeth Schramm, and Prof. Dr. Karl Wegscheider for serving as advisory board members, as well as Sarah Mannion for copy-editing the manuscript.

Author details

1. Department of Psychiatry and Psychotherapy, Research Group Psychotherapy and Health Services Research, Medical Center – University of Freiburg, Hauptstraße 5, D-79104 Freiburg, Germany.
2. Department of Public Health and Health Education, University of Education Freiburg, Kunzenweg 21, D-79117 Freiburg, Germany.
3. Department of Medical Psychology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, D-20246 Hamburg, Germany.
4. Department of Neuropsychiatry, Kochi Medical School, Kohasu, Okocho, Nankokushi, Kochi 783-8505, Japan.
5. Department of Psychiatry and Psychotherapy, University Medical Center Tübingen, Calwerstraße 14, D-72072 Tübingen, Germany.

Received: 20 August 2015 Accepted: 2 October 2015
Published online: 23 October 2015

References

1. Solomon DA, Keller MB, Leon AC, Mueller TI, Lavoir PW, Shea MT, et al. Multiple recurrences of major depressive disorder. AJP. 2000;157:229–33.
2. Kessing LV, Andersen PK. Predictive effects of previous episodes on the risk of recurrence in depressive and bipolar disorders. Curr Psychos Ther Rep. 2003;3:123–30.
3. Bitzer EM, Grobe TG, Neusser S, Miethe I, Schwartz FW. BARMER GEK Report. Krankenhaus 2011. Nov. St. Augustin: Asgard-Verlag. 2011.
4. Härter M, Sitta P, Keller F, Metzger R, Wiegand W, Schell S, et al. Psychiatric-psychotherapeutic inpatient treatment for depression: Process and outcome quality based on a model project in Baden-Württemberg. Nervenarzt. 2004;75:1083–91.
5. DGPPN, BÄK, KBV, AWMF, DBPQ, DBGM, DEGAM, DGP, DGPS, DGWR, editor. für die Leitliniengruppe Unipolare Depression. S3-Leitlinie/Nationale VersorgungsLeitlinie Unipolare Depression-Langfassung. Berlin: DGPPN; A2Q, AWMF; 2009.
6. McFarlane WR, Dushay RA, Deakin SM, Stasguy P, Luekers EP, Toran J, et al. Employment outcomes in family-aided assertive community treatment. Am J Orthopsychiatr. 2002;70:203–14.
7. Pitchel-Walz G, Leucht S, Baumli J, Kissing W, Engel RR. The effect of family interventions on relapse and rehospitalization in schizophrenia – a meta-analysis. Schizophr Bull. 2001;27:73–92.
8. Reinares M, Colom F, Sánchez-Moreno J, Torrent C, Martínez-Arán A, Cormes M, et al. Impact of caregiver group psychoeducation on the course and outcome of bipolar patients in remission: a randomized controlled trial. Bipolar Disord. 2008;10:51–19.
9. Pharaoh F, Man J, Rathbone J, Wong W. Family intervention for schizophrenia. Cochrane Database Syst Rev. 2010;1–156.
10. Lucksted A, McFarlane W, Downin D, Dixon L. Recent developments in family psychoeducation as an evidence-based practice. J Mental Fam Ther. 2012;38:101–21.
11. Gasque-Carter KD, Curlee MB. The educational needs of families of mentally ill adults: the South Carolina experience. Psych Serv. 1999;50:520–40.
12. Wittmund B, Bischkopf J, Angermeyer MC. Educational needs among spouses of depressive patients and their illness models of depression. Gesundheitswesen. 2001;63:356–41.
13. Frank F, Hasenmüller M, Kaiser M, Ries Z, Bitzer EM, Hölzel L. Psychoeducation for relatives of patients with depressive disorders: a focus group study on information demands. Psychother Psych Med. 2015;10:55–1557787.
14. Perlick DA, Rosenheck RA, Clarkin JF, Maclejewski PW, Sirey J, Stuening E, et al. Impact of family burden and affective response on clinical outcome among patients with bipolar disorder. Psychiatr Serv. 2004;55:1029–35.
15. Moller-Leimkühler AM. Multivariate prediction of relatives’ stress outcome one year after first hospitalization of schizophrenic and depressed patients. Eur Arch Clin Neurosci. 2006;263:122–30.
16. Hooley JM. Expressed emotion and relapse of psychopathology. Ann Rev Clin Psych. 2007;2:329–30.
17. Frank F, Rummel-Kluge C, Berger M, Bitzer EM, Hölzel LP. Provision of group psychoeducation for relatives of patients in inpatient depression treatment – a cross-sectional survey of acute care hospitals in Germany. BMC Psychiatry. 2014;14:143.
18. Nezu AM, Nezu CM, D’Zurilla TJ. Problem-solving therapy: a treatment manual. New York: Springer; 2012.
19. Hegel M, Baretz J, Oxman T, Myoruns-Wallis L, Gath D. Problem-solving treatment for primary care (PS-PC); a treatment manual for depression. Hanover, NH: Dartmouth University; 1999.
20. Maloff JM, Thorsteinson EB, Schutte NS. The efficacy of problem solving therapy in reducing mental and physical health problems: a meta-analysis. Clin Psychol Rev. 2007;27:46–57.
21. Elliott TR, Brossard D, Berry JW, Fine PR. Problem-solving training via videoconference for family caregivers of persons with spinal cord injuries: a randomized controlled trial. Behav Res Ther. 2008;46:1220–9.
22. Wilms HU, Wittmund B, Angermeyer MC. Psychiatric diagnoses in spouses of psychotic patients. Verhaltenstherapie und Verhaltnsmedizin. 2001;22:35–71.
23. Brown GW, Birley JLT, Wing JK. Influence of family life on the course of schizophrenic disorders: a replication. Br J Psych. 1972;121:241–58.
24. Vaughn CE, Leff JP. The influence of family and social factors on the course of psychiatric illness: A comparison of schizophrenic and depressed neurotic patients. Br J Psych. 1976;129:125–37.
25. Edwards P, Roberts I, Clarke M, DiGuiseppi C, Pratap S, Wentz R, et al. Methods to increase response rates to postal questionnaires. Cochrane Database Syst Rev. 2007. doi:10.1002/14651858.MR000008.pub4.
26. Simon GE, Katon WJ, Vonkoff M, Unützer J, Lin EHB, Waiker EA, et al. Cost-effectiveness of a collaborative care program for primary care patients with persistent depression. Am J Psych. 2001;158:1638–44.
27. Shimodera S, Futakawa TA, Mino Y, Shimizu K, Nishida A, Inoue S. Cost-effectiveness of family psychoeducation to prevent relapse in major depression: results from a randomized controlled trial. BMC Psych. 2012;12:420.
28. Park M, Unützer J. Hundred forty eight more days with depression: the association between marital conflict and depression-free days. Int J Geriatr Psychiatry. 2014;29:1271–7.
29. Kroenke K, Spitzer R, Williams J. The PHQ-9 validity of a brief depression severity measure. J Gen Intern Med. 2001;16:606–13.
30. Lave JR, Frank RG, Schuberg HC, Kamlet MS. Cost-effectiveness of treatments for major depression in primary care practice. Arch Gen Psychiatri. 1998;55:645–51.
31. Vannoy SD, Arean P, Unützer J. Advantages of using estimated depression-free days for evaluating treatment efficacy. Psychiatri Serv. 2010;61:1160–3.
32. Lowe B, Grave K, Zipfel S, Wiltse S, Loerch B, Herzog W. Diagnosing ICD-10 depressive episodes: superior criterion validity of the patient health questionnaire. Psychiatr Psychoon. 2004;73:386–90.
33. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington DC: American Psychiatric Association; 2013.
34. Seid H, Bowles D, Bock JQ, Brutsclinder C, Greinier W, Koenig HH, et al. FIMA – questionnaire für health-related resource use in an elderly population: development and pilot study. Gesundheitswesen. 2015;77:46–52.
35. Roick C, Killian R, Matschinger H, Bernett S, Mory C, Angermeyer MC. German adaptation of the client sociodemographic and service receipt inventory – an instrument for the cost of mental health care. Psychiat Prax. 2001;28:840–9.
36. Scheidt-Nave C, Kamtsiuris P, Göwald A, Hölling H, Lange M, Busch MA, et al. German health interview and examination survey for adults (DEGS) - design, objectives and implementation of the first data collection wave. BMC Public Health. 2012;12:730.
37. Hirschfeld RMA, Montgomery SA, Keller MB, Kasper S, Schatzberg AF, Möller HJ, et al. Social functioning in depression: a review. J Clin Psychiatry. 2000;61:268–75.
38. Mousavi S, Chatterji S, Verdes E, Tandon A, Patel V, Ustun B. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet. 2007;370:851–8.
39. Üstün TB. Measuring health and disability: manual for WHO disability assessment schedule WHODAS 2.0. Geneva: WHO; 2010.
40. Feldmann R, Buchkremer G, Münneker-Hügel E, Hornung P. Family expressed emotion questionnaire. Diagnostica. 1995;41:334–48.
51. Bachmann S, Bottmer C, Jacob S, Schröder J. Perceived criticism in schizophrenia: a comparison of instruments for the assessment of the patient’s perspective and its relation to relatives’ expressed emotion. Psychiatry Res. 2006;142:167–75.
52. Hooley JM, Teasdale JD. Predictors of relapse in unipolar depressives: expressed emotion, marital distress, and perceived criticism. J Abnorm Psychol. 1989;98:229–35.
53. Moher D, Hopewell S, Schulz KF, Montori V, Gatzschke PC, Devereaux PJ, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol. 2010;63:e1–37.
54. Sczufla M, Menezes PR, Almeida OP. Caregiver burden in an elderly population with depression in Sao Paulo, Brazil. Soc Psychiatry Psychiatr Epidemiol. 2002;37:416–22.
55. Bischkopf J, Wittmund B, Angermeyer MC. Everyday life with the depression of one’s spouse. Psychotherapeut. 2002;47:11–5.
56. Schmid R, Spielß H, Cording C. Between responsibility and delimitation: emotional distress of caregivers. Psychiatr Prax. 2005;32:272–80.
57. Vaghefoer R, Bährer E. Construction and test statistical evaluation of a short version of the SCL-90-R. Z Kli Psych Psychoth. 2001;49:115–24.
58. Bernet S, Kilian R, Matschinger H, Moro C, Röck C, Angermeyer MC. The assessment of burden on relatives of mentally ill people: the German version of the Involvement Evaluation Questionnaire (IEQ-EU). Psychiatr Prax. 2001;28:97–101.
59. van Willigenberg B, Schene AH, Koeter M, Vázquez-Barquero JL, Knudsen HC, Lasalvia A, et al. Caregiving in schizophrenia: development, internal consistency and reliability of the Involvement Evaluation Questionnaire-European Version EPSILON Study 4. Br J Psych. 2000;177:s21–7.
60. Wittmund B, Wilms H-U, Moro C, Angermeyer MC. Depressive disorders in spouses of mentally ill patients. Soc Psychiatry Psychiatr Epidemiol. 2002;37:177–82.
61. Kuipers E, Onwumere J, Bebbington P. Cognitive model of caregiving in psychosis. Br J Psych. 2010;196:259–65.
62. Graf A. A psychometric test of a German version of the SPSI-R. ZDOP. 2003;24:277–91.
63. D’Zurlita TJ, Nezu AM, Maydeu-Olivares A. Social problem-solving inventory–revised (SPSI-R). New York: Multi-Health Systems; 2002.
64. Griffiths KM, Christensen H, Jorm AF, Evans K, Groves C. Effect of web-based depression literacy and cognitive–behavioural therapy interventions on stigmatising attitudes to depression. Br J Psych. 2004;185:342–9.
65. Hesse K, Klingberg S. Examining the cognitive model of caregiving—a structural equation modelling approach. Psychiatry Res. 2014;217:171–6.
66. Lobban F, Barrowclough C, Jones S. Assessing cognitive representations of mental health problems. II. The illness perception questionnaire for schizophrenia: relatives’ version. Br J Clin Psychol. 2005;44:163–79.
67. Wiedemann G, Rayki O, Feinstein E, Höhlweg K. The family questionnaire: development and validation of a new self-report scale for assessing expressed emotion. Psychiatry Res. 2002;109:265–79.
68. Linden M, Walter M, Fritz K, Muschalla B. Undesired treatment effects in behavior group therapy: Frequency and spectrum. Nervenarzt. 2015; doi:10.1007/s00115-015-4297-6.
69. Graf von der Schulenburg JM, Greiner W, Jost F, Klusen N, Künin M, Leidl R, et al. German recommendations on health economic evaluation: third and updated version of the Hanover Consensus. Value Health. 2008;11:539–44.
70. Bock JO, Bretschneider C, Seidl H, Bowles D, Holle R, Greiner W, et al. Calculation of standardised unit costs from a societal perspective for health economic evaluation. Gesundheitswesen. 2015;77:53–61.
71. Hölzel L, Wilk J, Kriston L, Weck F, Frank F. Simulierte Therapiesituationen zur Messung therapeutischer Kompetenz. 9 Workshopkongress für Klinische Psychologie und Psychotherapie & 33. Dresden: Symposium der Fachgruppe Klinische Psychologie und Psychotherapie der DGP; 2015.